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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016with resolution of AKI, we observed a persistence of macrophages
and T cells (>10days).
Conclusions: The amount of renal epithelial cells in the urine seems
to directly reﬂect tissue damage in AKI. Immune cells can be
monitored in the urine of patients with AKI and persisted longer
than the renal injury itself. This suggests that immune cells
participate in mediating damage and tissue repair in human AKI.
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Introduction: The mechanism of injury to podocytes in focal
segmental glomerulosclerosis (FSGS) remains unclear. Both B7.1
(CD80) and suPAR have been proposed to cause FSGS but these
ﬁndings have not been validated. To survey these markers as po-
tential mediators of podocyte injury and as an aid to histologic
diagnosis of FSGS we evaluated the immunohistochemical expres-
sion of (1) B7-1 and suPAR in native and transplant kidney bi-
opsies, and (2) suPAR in an experimental mouse model of FSGS.
Methods: Consecutive kidney biopsies from the surgical pathology
ﬁles were selected for study groups of FSGS (n¼10) and early post-
transplant recurrent FSGS (n¼10). Native kidney biopsies with
membranous nephropathy (MN) (n¼10) and minimal change dis-
ease (MCD (n¼5), and 6 month post-transplant protocol biopsies
with normal morphology [n¼10] served as controls. Immunostains
for B7.1 and suPAR were performed on formalin-ﬁxed parafﬁn-
embedded and frozen sections with immunoperoxidase (IHC) or
immunoﬂuorescent (IF) methodology and the localization of the
positive signal was determined via co-stain with podocyte marker
synaptopodin. Appropriate positive method controls were avail-
able. In addition, uPAR expression was assessed in the kidneys of
wild type and suPAR deﬁcient (suPAR -/-) mice infused with
suPAR. The mouse kidneys were also evaluated by electron mi-
croscopy in conjunction with renal functional studies.
Results: B7.1 was not expressed in native kidneys with FSGS or
MCD or in transplant kidneys with recurrent FSGS. In MN, B7.1
was localized only to the immune deposits. No apparent suPAR
immunoreactivity was present in native kidneys or recurrent FSGS.
suPAR infusion did not produce proteinuria or effacement of
podocytes in wild type or suPAR deﬁcient mice. uPAR was
detected by IHC along the glomerular endothelial cells but not in
podocytes in wild type mice while uPAR stains remained negative
in suPAR deﬁcient mice even after suPAR injection.
Conclusions: The data suggest that B7.1 and suPAR may not play a
signiﬁcant role in podocyte injury in native and transplant kidneys
with FSGS. B7.1 and suPAR immunostains have a limited value as
diagnostic immunophenotypical markers in routine kidney biopsies
with FSGS and recurrent FSGS post-transplant.
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Introduction: The relevance of oxidative stress in systemic lupus
erythematosus (SLE) in humans is not fully understood. Moreover,
none of the previous studies have speciﬁcally studied the impact of
oxidative stress in patients of lupus nephritis. We conducted this
study to evaluate the markers of oxidative stress in patients of SLE
with or without lupus nephritis and to correlate them with clinical
presentation, disease activity, and type & severity of renal
manifestations.
Methods: This was a prospective study including patients diag-
nosed to have SLE on the basis of ACR criteria. The study partic-
ipants were divided into two groups depending on presence or
absence of renal involvement, which was deﬁned as either abnor-
malities in renal function test (serum creatinine$1.2mg/dl) or urine
examination (urine protein excretion $500mg/day or presence of
RBCs in urine) along with renal biopsy evidence of lupus nephritis.
After inclusion, patient’s particulars were noted including clinical
manifestations, investigations, SLE Disease Activity Index (SLE-
DAI), details of renal involvement, renal biopsy, treatment received
and the outcome. In both the groups, an additional 5 ml of venous
blood sample was drawn after overnight (8-10 hours) fasting for
analyzing the markers of oxidative stress. We studied Malondial-
dehyde (MDA) and Isoprostane as markers of lipid peroxidation;
reactive nitrogen intermediates (RNI) as markers of oxidative pro-
tein damage; 8-hydroxy deoxy guanosine as marker of oxidative
DNA damage and Superoxide dismutase (SOD) as a marker of
antioxidant activity.
Results: During the study period a total of 120 cases were included
(60 without lupus nephritis, 60 with lupus nephritis). The mean age
of study population was 29  9 years and 115 were females.
SLEDAI was signiﬁcantly higher in patients with nephritis as
compared to non-nephritis group. The mean values of serum MDA,
8-Isoprostane, 8-Hydroxy 2-deoxyguanosine and RNI were signif-
icantly higher in nephritis group, while there was no difference in
the levels of SOD. Signiﬁcant positive correlations were observed
between RNI and SLEDAI score (r ¼ 0.333, p<0.01), and MDA and
SLEDAI score (r ¼ 0.269, p<0.01), while none of the markers
showed signiﬁcant correlation with serum creatinine. There was no
signiﬁcant correlation between these markers and severity of renal
dysfunction, while 8-Hydroxy 2-deoxy guanosine levels showed
signiﬁcant negative correlation with degree of proteinuria (r¼
-0.345; p value 0.007). MDA levels were signiﬁcantly higher in
patients with proliferative lupus nephritis as compared to non
proliferative nephritis. During six months follow-up, we noted 7
deaths in nephritis group as compared to none in non-nephritis
group. The mean value of 8-Hydroxy 2-deoxy guanosine was
signiﬁcantly higher in those who died; however there was no sig-
niﬁcant difference in other oxidative markers.
Conclusions: SLE patients with nephritis have higher levels of
oxidative stress. Increased oxidative stress in nephritis patients
correlates more with SLEDAI than with type or severity of renal
dysfunction.
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Introduction: Systemic lupus erythematosus (SLE) is an autoim-
mune disease characterized by an acquired IL-2 deﬁciency in the
peripheral lymphoid organs and peripheral blood of murine and
human SLE (Humrich et al. 2010, von Spee-Mayer et al. 2015).
Kidney-inﬁltrating CD4+T cells play a crucial role in the progres-
sion of lupus nephritis (LN). However, the role of kidney- inﬁl-
trating T cells in the pathogenesis of LN is still not completely
understood. The aim of this study was to investigate whether an IL-
2 deﬁciency is also present in the inﬂamed kidney, thereby
contributing to an impaired intrarenal Treg function and renal
inﬂammation. Furthermore it was investigated if an IL-2-based
immunotherapy can directly act on intrarenal Treg and whether
this has consequences on the kidney inﬂammation.
Methods: Intrarenal CD4+ T cells phenotype of (NZBxNZW) F1
mice (NZB/W) with active LN was assessed and the in vitro IL-2
production of intrarenal CD4+CD44+ T cells were determined by
ﬂow cytometry. Furthermore, NZB/W mice were treated with re-
combinant IL-2 for a total of 31 days. Kidneys were histological
scored using the activity index (AI) and the intrarenal CD4+ T cell
phenotype was assessed in IL-2 treated mice compared to control
mice.
Results: Intrarenal Treg exhibit characteristic signs of IL-2 depri-
vation in parallel to a progressive hyperactivity of intrarenal Tcon
with disease progression. These Treg defects were associated with a
diminished production of IL-2 and an increased production of IFNg
by kidney-inﬁltrating Tcon. Furthermore, IL-2 therapy could in-
crease the frequency of intrarenal natural CD25+Helios+Treg,
strongly reduced the hyperactivity of intrarenal Tcon, ultimately
resulted in a reduced histological AI and prolonged the survival of
IL-2 treated lupus mice.
Conclusions: Our data indicate that on the one hand an IL-2 deﬁ-
ciency is also present in the inﬂamed kidney, thereby contributing
to renal inﬂammation. On the other hand, long term IL-2 treatment
is able to reduce hyperactivity of intrarenal Tcon and to diminish
kidney inﬂammation in lupus prone mice. This shows the close
relation between intrarenal IL-2 deﬁciency and resultant Treg de-
fects, the Tcon hyperactivity and the severity of LN. These results
also provide additional rationales for an IL-2 based immunotherapy
to treat patients with SLE, in particular with renal involvement.
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temic lupus erythematosus (SLE) that is usually treated with an
extended course of intravenous (IV) cyclophosphamide (CYC).
Given the side effects of high dose cyclophosphamide, we evaluated
the efﬁcacy of a course of low ﬁxed dose IV CYC prescribed as a
remission-inducing treatment, followed by (AZA) as a remission-
maintaining agent.
Methods: In this single center retrospective (january 2010 to
january 2014) clinical study, we evaluated 40 SLE patients with
proliferative glomerulonephritis who were given ﬁxed low dose IV
CYC regimen (500 mg 6 monthly pulses) followed by azathioprine
(AZA). AZA (2mg/kg/day) was started 2 weeks after the last CYC
injection. Oral prednisone was also given, beginning at a dose of
1 mg/kg per day and then tapering over a period of months to
alternate-day low dose maintenance therapy. Remission was deﬁned
as <10 red blood cells per high power ﬁeld, no cellular casts, and
proteinuria <1 g/day. Treatment failure was deﬁned as requiring
supplemental immunosuppression, doubling of the serum creati-
nine, or death. The renal relapse was deﬁned as doubling of the
urine protein-to-creatinine ratio or by an increase in the serum
creatinine to 1 & 1/2 times above normal.
Results: Mean serum creatinine at the time of initiating treatment
was 1.8 mg/dL. and mean urine protein excretion of 3.5 g/day. 7 of
the 40 patients (17.5%) experienced treatment failure, while rest of
all patients achieved remission (partial or complete) during induc-
tion phase. All seven treatment failure patients progressed to CKD,
as they could not afford other therapies/modalities available for
further treatment. Maintenance therapy with azathioprine was well
tolerated. 7 of 33 patients in remission developed renal ﬂares which
were treated successfully with pulse steroids followed by tapering
of steroids over 6 months.
Conclusions: Cyclophosphamide as an induction regimen followed
by maintenance with AZA is a viable and efﬁcient agent for the
treatment of proliferative lupus nephritis in a developing world
with economic constraints.
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Introduction: Lupus nephritis (LN) is one of the most serious
complications of systemic lupus erythematosus (SLE). Local MHC II
upregulation and a T cell rich inﬁltration suggest an antigen-spe-
ciﬁc immune response against kidney structures. Nevertheless, no
renal autoantigen is known at present.
Methods: The TCRß repertoire of peripheral blood and urinary T
cells was analyzed by TCRß chain sequencing and subsequent
sequence analysis. T cells from SLE Patients were stimulated with
different kidney lysates. Reactivity of T cells upon antigen stimu-
lation was tested using 3H+ Thymidin uptake in T cell libraries and
by detection of the activation markers CD40L and CD69 by ﬂow-
cytometry. Further renal candidate autoantigens were identiﬁedS21
